Profile data is unavailable for this security.
About the company
Frontage Holdings Corporation is a holding company. It provides laboratory and related services to pharmaceutical and agrochemical companies, as well as bioequivalence clinical and chemical services. The Company has two main divisions: Global Laboratory Services and Global Drug Discovery & Development Services. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The Global Drug Discovery & Development Services division includes Drug Development Unit, the Drug Discovery Unit, and the Pharmaceutical Product Development Unit. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Drug Development Unit includes drug metabolism and pharmacokinetics, Safety and Toxicology. The Company's segments include North America and Europe and PRC.
- Revenue in HKD (TTM)1.98bn
- Net income in HKD29.97m
- Incorporated2018
- Employees1.54k
- LocationFrontage Holdings Corp700 Pennsylvania DriveExton 19341-1129United StatesUSA
- Phone+1 (610) 232-0100
- Fax+1 (610) 232-0101
- Websitehttps://www.frontagelab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B&K Corp Ltd | 295.26k | -206.59m | 1.10bn | 100.00 | -- | 11.54 | -- | 3,737.66 | -1.76 | -1.76 | 0.0025 | 0.8128 | -- | -- | -- | -- | -- | -- | -- | -- | 92.34 | -- | -69,968.59 | -- | -- | -- | 0.0371 | -- | -44.70 | -- | -101.78 | -- | -- | -- |
| Brii Biosciences Ltd | 0.00 | -425.02m | 1.12bn | 96.00 | -- | 0.3965 | -- | -- | -0.5839 | -0.5839 | 0.00 | 3.91 | 0.00 | -- | -- | 0.00 | -14.05 | -49.92 | -14.09 | -54.57 | -- | -- | -- | -12,750.27 | -- | -- | 0.003 | -- | -100.00 | -- | -190.66 | -- | -33.13 | -- |
| Kintor Pharmaceutical Ltd | 12.43m | -189.00m | 1.37bn | 136.00 | -- | 5.04 | -- | 110.36 | -0.437 | -0.437 | 0.0287 | 0.5461 | 0.0194 | 10.66 | 1.06 | 73,964.33 | -29.53 | -47.72 | -44.54 | -55.96 | -55.12 | -36.16 | -1,521.00 | -8,974.73 | 0.4222 | -33.76 | 0.2881 | -- | -- | -- | 85.36 | -- | -53.11 | -- |
| Wuhan YZY Biopharma Co Ltd | 164.04m | -88.28m | 1.40bn | 106.00 | -- | -- | -- | 8.56 | -0.4554 | -0.4554 | 0.8462 | -0.1602 | 0.5805 | 11.54 | 13.96 | 1,451,646.00 | -31.24 | -- | -133.35 | -- | 63.96 | -- | -53.82 | -- | 0.9019 | -24.38 | 1.21 | -- | -- | -- | 49.09 | -- | -- | -- |
| HighTide Therapeutics Inc | 0.00 | -329.38m | 1.45bn | 57.00 | -- | 3.65 | -- | -- | -0.7286 | -0.7286 | 0.00 | 0.6934 | 0.00 | -- | -- | 0.00 | -49.50 | -- | -63.55 | -- | -- | -- | -- | -- | -- | -- | 0.2129 | -- | -- | -- | 59.35 | -- | -- | -- |
| Immunotech Biopharm Ltd | 0.00 | -252.84m | 1.57bn | 173.00 | -- | -- | -- | -- | -0.4518 | -0.4518 | 0.00 | -0.2878 | 0.00 | -- | -- | 0.00 | -37.04 | -36.20 | -186.73 | -45.67 | -- | -- | -- | -- | 0.0712 | -6.63 | 1.48 | -- | -- | -- | 44.18 | -- | 5.95 | -- |
| Cloudbreak Pharma Inc | 78.15m | -326.92m | 1.92bn | 60.00 | -- | -- | -- | 24.58 | -0.3897 | -0.3897 | 0.0932 | -3.08 | -- | -- | -- | 1,532,333.00 | -- | -- | -- | -- | -- | -- | -418.33 | -- | -- | -- | 19.44 | -- | -- | -- | 23.40 | -- | -- | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 126.82m | -342.42m | 1.96bn | 195.00 | -- | 3.06 | -- | 15.48 | -0.8705 | -0.8705 | 0.3221 | 1.48 | 0.148 | -- | 3,865.48 | 812,920.80 | -40.09 | -- | -51.56 | -- | -- | -- | -270.79 | -- | -- | -- | 0.2236 | -- | 19,109.59 | -- | 16.76 | -- | -- | -- |
| Mabpharm Ltd | 479.58m | -31.09m | 2.10bn | 383.00 | -- | 18.81 | 57.03 | 4.39 | -0.0076 | -0.0076 | 0.1163 | 0.0271 | 0.4209 | 0.4659 | 4.05 | 1,522,484.00 | -2.73 | -19.62 | -4.02 | -25.69 | 86.40 | -- | -6.48 | -211.59 | 0.6906 | -1.58 | 0.7552 | -- | 196.27 | -- | 38.89 | -- | -12.13 | -- |
| Jiangsu Recbio Technology Co Ltd | 12.33m | -739.75m | 2.17bn | 507.00 | -- | 10.61 | -- | 176.26 | -1.55 | -1.55 | 0.0258 | 0.4242 | 0.006 | -- | -- | 23,220.05 | -36.26 | -31.31 | -64.03 | -37.31 | -- | -- | -5,990.59 | -- | 0.2767 | -100.74 | 0.8254 | -- | -- | -- | 1.67 | -- | 16.82 | -- |
| Frontage Holdings Corp | 1.98bn | 29.97m | 2.20bn | 1.54k | 73.12 | 0.8238 | 6.99 | 1.11 | 0.0148 | 0.0148 | 0.9735 | 1.31 | 0.4545 | 60.36 | 3.97 | 1,267,467.00 | 0.6902 | 3.05 | 0.8654 | 3.64 | 27.78 | 32.14 | 1.52 | 6.84 | 1.22 | 1.97 | 0.2861 | 0.00 | -1.90 | 20.48 | -92.68 | -46.72 | 13.29 | -- |
| Antengene Corp Ltd | 95.43m | -258.61m | 2.34bn | 152.00 | -- | 2.70 | -- | 24.56 | -0.4162 | -0.4162 | 0.1536 | 1.28 | 0.0619 | 1.51 | 3.20 | 564,657.30 | -16.77 | -48.14 | -19.52 | -53.06 | 78.54 | -- | -271.00 | -1,460.93 | 4.41 | -- | 0.2346 | -- | 36.62 | -- | 45.07 | -- | 259.46 | -- |
| Hanx Biopharmaceuticals (Wuhan) Co Ltd | -100.00bn | -100.00bn | 2.62bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.30 | -- | -- | -- |
| Clover Biopharmaceuticals Ltd | 58.57m | -1.03bn | 2.86bn | 243.00 | -- | -- | -- | 48.76 | -0.8194 | -0.8194 | 0.0466 | -1.49 | 0.0433 | 0.0547 | 47.89 | 195,233.00 | -76.07 | -75.37 | -- | -188.14 | 62.57 | -- | -1,756.85 | -13,419.00 | 0.2541 | -- | -- | -- | -2.13 | -- | -552.11 | -- | -24.90 | -- |
| BioDlink International Co Ltd | 1.21bn | 8.21m | 3.25bn | 604.00 | 370.89 | 3.92 | 35.55 | 2.69 | 0.0113 | 0.0113 | 1.66 | 1.07 | 0.7275 | 2.35 | 5.49 | 1,975,331.00 | 0.495 | -11.37 | 0.6586 | -14.89 | 71.10 | 73.14 | 0.6805 | -24.91 | 1.68 | 1.83 | 0.3519 | -- | 40.70 | 89.20 | 192.05 | -- | 27.04 | -- |
| Hua Medicine | 419.32m | 1.22bn | 3.30bn | 285.00 | 2.55 | 2.56 | 2.62 | 7.86 | 1.23 | 1.23 | 0.4248 | 1.22 | 0.2411 | 1.76 | 5.71 | 2,495,966.00 | 69.99 | -21.83 | 82.64 | -25.31 | 52.55 | -- | 290.30 | -395.24 | 7.00 | -- | 0.2038 | -- | 234.02 | -- | -18.42 | -- | -17.81 | -- |
Data as of Feb 16 2026. Currency figures normalised to Frontage Holdings Corp's reporting currency: Hong Kong Dollar HKD
0.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 2.75m | 0.14% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 345.55k | 0.02% |
| DFA Australia Ltd.as of 31 Dec 2025 | 132.61k | 0.01% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
